Darrin Disley
Angel Investor
Cambridge, United Kingdom
Darrin Disley is a seed investor in Cambridge focused on Biotechnology and Health Care. Darrin Disley is based out of Cambridge, Cambridgeshire, and is the Executive Chairman and Director of Cardiogeni. Darrin previously worked at Mogrify as Chief Executive Officer, Director, and Investor. Darrin Disley attended the University of Cambridge.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Darrin Disley invests in
Stages Darrin Disley invests in
Countries Darrin Disley invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $458k–$3.7M
Investment Focus
Industry
- Biotechnology 3 (60%)
- Health Care 2 (40%)
- Big Data 1 (20%)
- Genetics 1 (20%)
- Analytics 1 (20%)
Stage
- Seed 3 (60%)
- Series A 1 (20%)
- Funding Round 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. | $17M / Series A / May 04, 2021 | ||
| Mogrify® has developed a proprietary suite of platform technologies that utilize a systematic big-data approach to direct cellular reprogramming (Rackham et al., Nature Genetics, 2016) and the maintenance of cell identity (Kamaraj et al., Cell Systems 2020). The platforms, MOGRIFY® and epiMOGRIFY®, developed over a 12-year period via amulti-national research collaboration, deploy next-generation sequencing, gene regulatory and epigenetic network data to enable the prediction of the transcription factors and growth factors required to produce any target human cell type from any source human cell type.The platforms can be used to enhance existing stem-cell forward programming methods, or bypass development pathways altogether, affecting a direct transdifferentiation between a mature cell type to another mature cell type.Mogrify is applying its proprietary and award-winning platforms to generate the functional cell types required to transform the lives of patients, by delivering a novel class of in vivo reprogramming therapies across ophthalmology, otology, metabolic and other areas of degenerative disease.Uniquely positioned to address a regenerative medicine market estimated to be worth $150 billion USD by 2028, Mogrify is commercializing its technology via a combination of in vivo reprogramming therapy development, co-development partnerships, as well as the exploitation of the platform in other therapeutic and non-therapeutic applications. | $3.7M / Seed / Feb 20, 2019 | ||
| Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-readyhuman cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation. | $458K / Seed / Nov 16, 2017 | ||
| Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive. | $1.8M / Sep 15, 2015 | ||
| Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive. | $582K / Seed / Aug 27, 2013 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Darrin Disley invest in?
Darrin Disley invests primarily in Biotechnology, Health Care and Big Data startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Darrin Disley's check size?
Darrin Disley typically joins rounds of $458k–$3.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Darrin Disley participates in.
How do I contact Darrin Disley?
Public channels for Darrin Disley include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Darrin Disley last invest?
The most recent investment recorded for Darrin Disley closed in May 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
